...$26.5 million series A round geared to helping them repeat their performance at hematology play FerroKin BioSciences Inc....
...board. CEO Hugh Rienhoff, who was CEO of FerroKin, formed Imago with other veterans of FerroKin...
...same virtual company model as at FerroKin, and that the idea for Imago came from FerroKin...

...oral metal chelator for transfusional iron overload. SHP602, which Shire gained in its acquisition of FerroKin BioSciences Inc....
...option from Meritage Pharma Inc. SHP602 Metal chelator Transfusional iron overload Ph II Shire; from FerroKin...

...it paid $100 million up front plus up to $225 million in milestones to acquire Ferrokin BioSciences Inc....
...Bergeron, according to Shiosaki. Bergeron has designed and developed a number of iron chelator analogs. "Ferrokin's...

...Shire has an option to license the programs $22M in funding over five years Oct-12 FerroKin BioSciences Inc....

...an equity investment; >$160M in milestones for each licensed program, plus double-digit royalties Preclin Apr-2012 FerroKin BioSciences Inc....

...its 1H12 report, Shire said that in April it completed the acquisition of hematology company FerroKin...
...$94.5 million in cash and up to $225 million in milestones (see BioCentury, March 19). FerroKin BioSciences Inc....

...Strategy Shire's iron backbone By Stephen Hansen Senior Writer Shire plc envisions FBS0701 from FerroKin BioSciences Inc. as...
...commercial hematology unit within its specialty pharmaceuticals business. Last month, Shire said it will acquire FerroKin...
...the cell membrane, allowing for structure-based drug design (see BioCentury, Sept. 15, 2008) . The FerroKin...

...Shire will acquire hematology company FerroKin for $100 million up front, plus up to $225 million...
...Factors VII, VIII, IX and X. Seaview Securities advised FerroKin (see BioCentury, Feb. 6). FerroKin BioSciences Inc....

...for Replagal agalsidase alfa to treat Fabry's disease and announcing plans to acquire hematology company FerroKin BioSciences Inc....

...Shire plc (LSE:SHP; NASDAQ:SHPGY) will acquire hematology company FerroKin BioSciences Inc. (San Carlos, Calif.) for $100 million up...
...ZFP) therapeutics targeting four genes -- Factors VII, VIII, IX and X. Seaview Securities advised FerroKin...